People · Operator
Named in public records as an officer, director or promoter · active 2013–2018 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pionyr Immunotherapeutics, Inc. | — | Other Health Care | Series B | $45.0M | $155.1M | 2017 |
| Pinta Biotherapeutics, Inc. | — | Biotechnology | Series B | $24.3M | $250.5M | 2013 |
| Santa Maria Biotherapeutics, Inc. | — | Biotechnology | Series B | $24.3M | $250.5M | 2013 |
| Nina Biotherapeutics, Inc. | — | Biotechnology | Seed | $3.4M | $39.0M | 2013 |
Carol F. Gallagher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carol F. Gallagher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Ciechanover | 3 | 5 |
| Beth F. Seidenberg | 3 | 4 |
| Eckard F. Weber | 3 | 4 |
| Gad F. Soffer | 3 | 3 |
| John F. McGrath | 3 | 3 |
| Joel F. Marcus | 3 | 3 |
| Christopher F. Haqq | 3 | 3 |
| Michael F. Powell | 1 | 6 |
| Steven P. James | 1 | 3 |
| Joshua F. Resnick, M.D. | 1 | 1 |
| Matthew F. Krummel, Ph.D. | 1 | 1 |
| Leon F. Chen, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.